Did you know autoimmune diseases impact 10% of the global population?

Zoom in on Abivax, a clinical-stage biotechnology company revolutionizing treatments for conditions like IBD with their lead drug, obefazimod.

Abivax was recently listed on Nasdaq, raising USD 236 million in the largest IPO by a French biotech. This marks Bryan Garnier’s 6th financing transaction with Abivax since 2020, and adds to our track record of over 20 IPOs and follow-ons led for European growth companies on the US NASDAQ.

Abivax is bringing new hope to autoimmune disease patients.

свернуть